Principal Investigator: Javier Oesterheld, MD (Carolina’s Medical Center/Levine Cancer Institute)
Patients who have recurrent or progressive disease following frontline treatment for osteosarcoma or Ewing sarcoma have a dismal prognosis, with less than one-fifth of patients achieving a long-term cure. Although many adolescents and young adults with localized bone or soft tissue sarcoma can become long-term survivors, more effective therapies are needed for patients who present with metastatic disease or whose tumors recur after completing therapy.
It is thought this combination will be more tolerable and effective than other relapsed regimen used to treat this population. This trial will look at this combination of nab-paclitaxel and gemcitabine in its ability to prevent the formation or growth of tumors in teenagers and young adults with relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and other soft tissue sarcomas. Markers for response to therapy are cutting edge in this trial and include blood tests to determine if the cancer is responding, computer-assisted imaging reviews to determine better ways to follow disease, and biomarkers on the tumor specimens to see if a response can be predicted.